CSIMarket
 


Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 
 

SYRS's Revenue Growth by Quarter and Year

Syros Pharmaceuticals Inc 's Revenue results by quarter and year




SYRS Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -0.75 7.80 5.70
III Quarter September 3.76 3.89 5.70 3.83
II Quarter June 2.83 6.28 5.16 3.19
I Quarter March 2.95 5.47 4.83 2.38
FY   9.54 14.89 23.49 15.10



SYRS Revenue third quarter 2023 Y/Y Growth Comment
Syros Pharmaceuticals Inc reported decrease in Revenue in the third quarter 2023 by -3.29% to $ 3.76 millions, from the same quarter in 2022.
The decrease in the third quarter 2023 Syros Pharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 144.38%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 158 other companies have achieved higher Revenue growth. While Syros Pharmaceuticals Inc ' s Revenue decline of -3.29% ranks overall at the positon no. 2352 in the third quarter 2023.




SYRS Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - 36.84 % 1017.65 %
III Quarter September -3.29 % -31.75 % 48.83 % 583.93 %
II Quarter June -54.94 % 21.71 % 61.76 % 593.48 %
I Quarter March -46.07 % 13.25 % 102.94 % 428.89 %
FY   - -36.61 % 55.56 % 662.63 %

Financial Statements
Syros Pharmaceuticals Inc 's third quarter 2023 Revenue $ 3.76 millions SYRS's Income Statement
Syros Pharmaceuticals Inc 's third quarter 2022 Revenue $ 3.89 millions Quarterly SYRS's Income Statement
New: More SYRS's historic Revenue Growth >>


SYRS Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - 36.84 % 48.83 %
III Quarter September 32.93 % -38.06 % 10.47 % 20.06 %
II Quarter June -4.07 % 14.81 % 6.83 % 34.03 %
I Quarter March - -29.87 % -15.26 % 366.67 %
FY (Year on Year)   - -36.61 % 55.56 % 662.63 %




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #159
Healthcare Sector #413
Overall #2352

Revenue Y/Y Growth Statistics
High Average Low
1021.65 % 144.38 % -66.39 %
(Dec 31 2020)   (Mar 31 2018)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #159
Healthcare Sector #413
Overall #2352
Revenue Y/Y Growth Statistics
High Average Low
1021.65 % 144.38 % -66.39 %
(Dec 31 2020)   (Mar 31 2018)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Syros Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
368.31 % 22.77 % -100 %
(Mar 31 2020)  


SYRS's III. Quarter Q/Q Revenue Comment
Syros Pharmaceuticals Inc achieved in the III. Quarter 2023 above company average sequential Revenue jump of 32.93%, to $ 3.76 millions, from $2.83 millions in the second quarter.
Syros Pharmaceuticals Inc is undergoing a remarkable growth, not just reporting better then average growth, and additionally improving speed, Carina Pires, Healthcare sector advisor located in Lisbon said.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Syros Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 238.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #90
Overall #238
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #90
Overall #238
Revenue Q/Q Growth Statistics
High Average Low
368.31 % 22.77 % -100 %
(Mar 31 2020)  


SYRS's III. Quarter Q/Q Revenue Comment
Syros Pharmaceuticals Inc achieved in the III. Quarter 2023 above company average sequential Revenue jump of 32.93%, to $ 3.76 millions, from $2.83 millions in the second quarter.
Syros Pharmaceuticals Inc is impressively improving, with recording better then normal increase, but also accelerating rate.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Syros Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 238.


Syros Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 8.80 $ 8.92 $ 12.37 $ 14.88 $ 23.44
Y / Y Revenue Growth (TTM) -62.47 % -64.65 % -48.74 % -36.65 % 9.6 %
Year on Year Revenue Growth Overall Ranking # 1381 # 376 # 635 # 261 # 1644
Seqeuential Revenue Change (TTM) -1.45 % -27.84 % -16.89 % -36.51 % -7.15 %
Seq. Revenue Growth (TTM) Overall Ranking # 2694 # 1306 # 2360 # 1302 # 2993




Cumulative Revenue growth Comment
Syros Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Syros Pharmaceuticals Inc 's annual Revenue decrease would be -62.47% year on year to $9 millions.

In the Healthcare sector 269 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 376 to 1381.

Revenue TTM Q/Q Growth Statistics
High Average Low
661.5 %
114.81 %
-64.65 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 151
Healthcare Sector # 270
Overall # 1381

Revenue TTM Y/Y Growth Statistics
High Average Low
661.5 %
114.81 %
-64.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 151
Sector # 420
S&P 500 # 2694
Cumulative Revenue growth Comment
Syros Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Syros Pharmaceuticals Inc 's annual Revenue drop would be -62.47% year on year to $9 millions.

In the Healthcare sector 269 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 376 to 1381.

Revenue TTM Q/Q Growth Statistics
High Average Low
661.5 %
114.81 %
-64.65 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 151
Healthcare Sector # 270
Overall # 1381

Revenue TTM Y/Y Growth Statistics
High Average Low
661.5 %
114.81 %
-64.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 151
Sector # 420
S&P 500 # 2694




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SYRS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for SYRS's Competitors
Revenue Growth for Syros Pharmaceuticals Inc 's Suppliers
Revenue Growth for SYRS's Customers

You may also want to know
SYRS's Annual Growth Rates SYRS's Profitability Ratios SYRS's Asset Turnover Ratio SYRS's Dividend Growth
SYRS's Roe SYRS's Valuation Ratios SYRS's Financial Strength Ratios SYRS's Dividend Payout Ratio
SYRS's Roa SYRS's Inventory Turnover Ratio SYRS's Growth Rates SYRS's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc-0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Bionexus Gene Lab Corp -0.83%$ -0.831 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions
Scientific Industries Inc -3.16%$ -3.165 millions
Akumin Inc -3.21%$ -3.205 millions
Syros Pharmaceuticals Inc -3.32%$ -3.315 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com